What we do
Be at the forefront of AI-driven precision immunology for drug discovery
Immune-mediated diseases affect hundreds of millions of people world-wide, but less than 12% of new drugs reach approval, largely due to insufficient pre-clinical understanding of the complex underlying disease biology.
You will be joining a stealth techbio therapeutics company aimed at disrupting drug discovery in the immunology space â by precisely understanding disease biology through iterative, causal discovery starting from realistic primary patient models. Our founders have authored several landmark publications in the precision medicine space, previously exited a precision medicine startup, and built a unique translational research program in a large pharmatech drug discovery company. As natives of both tech and bio spaces we deeply appreciate the unique irreducible challenges that come with both.
Consider joining us if you want to co-create innovative tech that addresses a critical unsolved problem at the root of drug discovery: effectively exploring the causal mechanisms of disease using more realistic biological models prior to designing therapeutics.
